HC Wainwright Reaffirms "Buy" Rating for Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $158.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 115.11% from the stock's previous close.

Other research analysts also recently issued reports about the stock. JPMorgan Chase & Co. began coverage on shares of Dianthus Therapeutics in a research note on Friday, September 11th. They set an "overweight" rating and a $135.00 price objective on the stock. Wedbush raised their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Citigroup assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a "buy" rating and a $156.00 target price for the company. Truist Financial upped their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Finally, Raymond James Financial reaffirmed a "strong-buy" rating and set a $131.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $129.83.

Dianthus Therapeutics Trading Down 1.7%

DNTH stock traded down $1.31 during midday trading on Thursday, hitting $73.45. 439,348 shares of the company's stock were exchanged, compared to its average volume of 927,719. Dianthus Therapeutics has a 12-month low of $32.22 and a 12-month high of $117.88. The firm has a 50 day moving average price of $100.75 and a 200-day moving average price of $94.49. The stock has a market capitalization of $4.03 billion, a price-to-earnings ratio of -17.64 and a beta of 1.35.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The business had revenue of $0.76 million for the quarter, compared to analysts' expectations of $0.30 million. On average, sell-side analysts forecast that Dianthus Therapeutics will post -3.81 EPS for the current fiscal year.

Insiders Place Their Bets

In other Dianthus Therapeutics news, CAO Edward Carr sold 20,000 shares of the firm's stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $101.38, for a total value of $2,027,600.00. Following the transaction, the chief accounting officer owned 20,000 shares of the company's stock, valued at $2,027,600. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $108.11, for a total value of $17,946,260.00. Following the completion of the transaction, the chief executive officer owned 65,292 shares of the company's stock, valued at approximately $7,058,718.12. The trade was a 71.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 242,429 shares of company stock worth $26,118,913. Corporate insiders own 3.02% of the company's stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. ABS Investment Management LLC acquired a new position in shares of Dianthus Therapeutics during the second quarter valued at $194,960,000. First Horizon Corp bought a new position in Dianthus Therapeutics in the 1st quarter valued at about $32,000. EFG International AG bought a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth about $49,000. GAMMA Investing LLC boosted its holdings in shares of Dianthus Therapeutics by 83.6% in the third quarter. GAMMA Investing LLC now owns 558 shares of the company's stock valued at $49,000 after acquiring an additional 254 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new position in shares of Dianthus Therapeutics in the second quarter valued at approximately $93,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company's approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus' lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.